Episode 54: All about 340B

In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients.

But over time, it has evolved into something much bigger.

We unpack how the program actually works, why it’s become a financial cornerstone for many hospital systems, and the growing tension with pharmaceutical companies like Pfizer and Johnson & Johnson. From contract pharmacy battles to questions around transparency and patient benefit, the 340B ecosystem sits at the center of one of the most complex, and controversial, debates in healthcare economics.

Because 340B isn’t just about drug discounts.

It’s about who captures value in the healthcare system and who it’s really meant to serve.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#340B #HealthcarePolicy #Pharma #DrugPricing #HealthEconomics #Biotech #HealthcareInnovation #PetriDishPerspectives #USHealthcare #PolicyExplained

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, biotech storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

Today, we are performing an autopsy on the 340B Drug Pricing Program.

Depending on who you ask, 340B is either the essential lifeline that keeps safety-net hospitals from going bankrupt, or it’s a predatory "rebate trap" that has ballooned into a $50 billion-plus opaque market. As of May 2026, the tension has reached a breaking point. With AbbVie’s high-profile lawsuit currently putting these discounts under a microscope, we need to understand how we got here, why the math is breaking, and what it means for the next decade of drug development.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

The Origin Story—The 1992 Compromise

To understand the 340B program, you have to go back to 1992. The U.S. was in the middle of a drug-pricing crisis (some things never change), and the Veterans Affairs (VA) was struggling to afford medications.

Congress passed the Veterans Health Care Act of 1992, and tucked inside was Section 340B of the Public Health Service Act. The intent was simple and noble: to allow "Covered Entities"—think safety-net hospitals, clinics for the uninsured, and specialized centers for HIV or black lung—to "stretch scarce federal resources as far as possible."

[The Mechanism of the Discount] In exchange for having their drugs covered by Medicaid, pharmaceutical manufacturers were required to provide deep discounts to these specific providers.

The discount is calculated using the Medicaid Drug Rebate formula. At a minimum, it’s about 23.1% off the Average Manufacturer Price (AMP) for brand-name drugs. But here is the kicker: if a manufacturer raises the price of a drug faster than inflation, there is an additional "inflationary penalty" that can effectively drive the price of the drug for a 340B hospital down to a penny.

For twenty years, this was a niche program. But in 2010, the "Big Bang" happened.

The Explosion—ACA and the Contract Pharmacy Loophole

Two things happened during the Affordable Care Act (ACA) era that fundamentally changed the "Systems Architecture" of 340B.

First, the definition of a "Covered Entity" expanded. Suddenly, thousands of additional hospitals qualified. Second—and this is the part that drives the current litigation—the government issued guidance allowing these hospitals to partner with Contract Pharmacies.

[The Arbitrage Machine] Previously, a hospital had to dispense the drug through its own on-site pharmacy. Now, they could partner with a Walgreens, a CVS, or a specialty pharmacy down the street.

Here is how the math works in the wild:

1. A patient (who doesn't even have to be low-income) goes to a 340B-eligible clinic.
2. The doctor writes a prescription for a high-cost specialty drug.
3. The patient fills it at a "Contract Pharmacy."
4. The manufacturer is forced to sell that drug to the hospital at the 340B ceiling price.
5. But the patient’s insurance pays the pharmacy the full commercial rate.

The difference—the spread—is kept by the hospital and the pharmacy. In 2010, there were fewer than 1,500 contract pharmacies. By 2026, there are over 30,000. The program has transformed from a safety-net for the poor into a profit-generator for some of the largest health systems in America.

Who is Impacted? The Stakeholder War

There are no "neutral" parties in 340B.

[The Manufacturers] For companies like Eli Lilly, AbbVie, and Roche, 340B is a massive "Gross-to-Net" (GTN) drain. When you see a company report $10 billion in sales but only $6 billion in "Net Revenue," 340B is often the largest culprit. Manufacturers argue that the program is being abused to fund hospital expansions and executive bonuses rather than lowering costs for patients.

[The Covered Entities (Hospitals)] Hospitals argue that without 340B revenue, they would have to shut down their oncology wards or pediatric units. They claim that the "Contract Pharmacy" model is the only way to reach patients in rural areas who can't drive 100 miles to the main hospital pharmacy.

[The Patients] This is the most controversial part. Does the 340B discount get passed to the patient at the counter? Often, no. Most 340B hospitals charge the patient (or their insurer) the full price and use the "savings" for other services. This has led to the bizarre reality where a "safety-net" program doesn't actually lower the out-of-pocket cost for the person receiving the drug.

The Legal Autopsy—AbbVie’s 2026 Lawsuit

This brings us to the present. We are currently watching AbbVie’s 340B lawsuit unfold in 2026.

AbbVie, following in the footsteps of companies like Sanofi and AstraZeneca, has placed 340B discounts and margins under a microscopic legal lens. The core of the argument is whether the government has the authority to force manufacturers to provide these discounts to third-party "Contract Pharmacies."

[The Legal Pivot] The manufacturers are arguing that the 1992 statute never mentioned pharmacies; it mentioned "Covered Entities." By allowing PBMs and retail pharmacies to take a cut of the 340B spread, the government has essentially created an illegal price-control mechanism that violates the manufacturers' property rights.

As of May 2026, this case is critical because it challenges the transparency of where that money goes. If AbbVie wins, it could force a massive "de-leveraging" of the hospital-pharmacy relationship, potentially clawing back billions in revenue for the pharma industry—or, if they lose, it could codify the contract pharmacy model forever.

The "Scientific Translator" Takeaways

If you are an analyst or a BD lead, how do you model 340B in 2026?

1. The "Duplicate Discount" Risk: One of the biggest technical headaches is the "Duplicate Discount." By law, a manufacturer shouldn't have to pay a 340B discount and a Medicaid rebate on the same pill. But because the systems are so fragmented, it happens constantly. Improving your claims-level data is no longer optional; it’s a financial necessity.
2. Portfolio Exposure: If your pipeline is heavily weighted toward "Physician Administered" drugs (Part B), you are more exposed to 340B than if you are in the "Retail" (Part D) space. You must "stress-test" your launch prices against a world where 50% of your volume might be sold at 340B rates.
3. The Transparency Tide: Regardless of the lawsuit outcome, the days of "340B Secrecy" are ending. We are seeing a push for a "National 340B Clearinghouse" to track every single pill from the factory to the patient's hand.

Outro

340B started as a small, well-intentioned paragraph in a 1992 bill. It has become the "Invisible Giant" of American healthcare—a multi-billion dollar ecosystem that everyone depends on but no one fully understands.

As we watch the AbbVie lawsuit move through the courts this year, remember: this isn't just about discounts. It’s about the very architecture of how we fund healthcare in this country.

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening. See you next Thursday. Good bye.

References

1. www.wikipedia.org
2. https://www.hrsa.gov/opa 
3. https://www.340bhealth.org/members/340b-program/overview/ 
4. https://hfs.illinois.gov/medicalproviders/pharmacy/340bfaq.html 
5. https://news.abbvie.com/2026-04-08-AbbVie-moves-to-close-loopholes-and-strengthen-accountability-in-340B-program